KUALA LUMPUR (Feb 9): TMC Life Sciences Bhd (KL:TMCLIFE) posted a net profit of RM6.56 million for its second quarter ended Dec 31, 2025 (2QFY2026), as quarterly revenue climbed to a record RM103.5 million.

Revenue rose 28.7% year-on-year from RM80.43 million, while the group swung into the black from a net loss of RM947,000 in 2QFY2025.

The group attributed the stronger performance to contributions across its specialties and cost-efficiency measures at Thomson Hospital Kota Damansara (THKD).

On the expense side, inventories and consumables rose 44.4% to RM37.92 million from RM26.26 million, while staff costs eased 3.1% to RM28.52 million compared with RM29.42 million a year earlier. Other operating expenses increased 11.2% to RM18.48 million from RM16.62 million.

No dividend was declared for the quarter.

For the first half of FY2026, TMC Life Sciences reported a net profit of RM10.97 million, sharply higher than RM1.99 million a year earlier, while revenue surged 25.6% to RM203.97 million from RM162.39 million.

Looking ahead, the group said it is adopting a balanced approach in engagements with payors, while diversifying revenue streams and driving further cost efficiencies. It remains optimistic about growth, supported by expanded capacity and ongoing development across key specialties at THKD.

The group also aims to broaden its customer mix by attracting more corporate and international patients, while strengthening partnerships with insurers to underpin sustainable growth.

Shares in TMC slipped half a sen or 1.1% to 46.5 sen on Monday, valuing the group at RM810 million. Over the past year, the stock has been largely unchanged.